Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00133900
Status:
UNKNOWN
Last Update Posted:
2009-07-28
First Post:
2005-08-22
Brief Title:
Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer HRPC Patients Receiving Chemotherapy
Sponsor:
Immunicon
Organization:
Immunicon
Study Overview
Official Title:
Circulating Tumor Cells and the Prediction of Overall Survival in Patients With Androgen Independent Prostate Cancer Entering Onto Chemotherapy
Status:
UNKNOWN
Status Verified Date:
2008-03
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IMMC-38
Brief Summary:
This study enrolled men with prostate cancer who had failed hormone therapy as shown by rising prostate-specific antigen PSA levels and who were about to start a new line of chemotherapy Blood was drawn prior to the patient receiving chemotherapy and then monthly thereafter for up to 18 months or until disease progression whichever occurred first The blood was tested to find circulating tumor cells CTC and to count them The circulating tumor cell levels were studied in relation to the patients overall survival Serum was also collected for PSA testing and additional blood samples were drawn to test for circulating endothelial cells and RNA was isolated for future gene expression testing
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None